Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MPI | P34949 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.37 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.37 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.37 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | ERN1 | O75460 | 2/20 | 0.34 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5118435 | 0.83 | CYP1A2 (0.42) | CYP3A4CYP2C19CYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL29878553 | 0.83 | CYP1A2 (0.42) | CYP3A4CYP2C19CYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL13521756 | 0.79 | ALDH1A1 (0.35) | CYP3A4CYP2C19ALDH1A1KDM4ECHRNB2 | |
| SCHEMBL31412448 | 0.79 | ALDH1A1 (0.35) | CYP3A4CYP2C19ALDH1A1KDM4ECHRNB2 | |
| SCHEMBL30424169 | 0.79 | CHRNB2 (0.33) | ALDH1A1CHRNB2CHRNA4KCNQ3KCNQ2 | |
| SCHEMBL29411195 | 0.78 | TDP1 (0.45) | CYP3A4CYP2C19CYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL899188 | 0.78 | TDP1 (0.45) | CYP3A4CYP2C19CYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL6631118 | 0.78 | UHRF1 (0.46) | CYP3A4CYP2C19CYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL29954921 | 0.78 | UHRF1 (0.46) | CYP3A4CYP2C19CYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL24052805 | 0.78 | ALDH1A1 (0.34) | CYP3A4ALDH1A1CHRNB2CHRNA4KCNQ3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| EP-4630410-A1 | POLQ INHIBITORS | Astrazeneca AB (SE) | 2025-10-15 | — | — | EP | disclosed |
| US-12414954-B2 | POLQ inhibitors | ASTRAZENECA AB (SE) | 2025-09-16 | — | — | US | disclosed |
| US-20250195530-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2025-06-19 | — | — | US | disclosed |
| US-20240366615-A1 | POLQ INHIBITORS | ASTRAZENECA UK LIMITED (GB) | 2024-11-07 | — | — | US | disclosed |
| WO-2024218503-A1 | SOLID FORMS OF AN ENZYME INHIBITOR AND SALTS THEREOF | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2024-10-24 | — | — | WO | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |
| US-20240327390-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2024-10-03 | — | — | US | disclosed |
| WO-2024121753-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2024-06-13 | — | — | WO | disclosed |
| EP-3929194-B1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2024-04-17 | — | — | EP | disclosed |
| US-6022967-A | 1-NITRO-2-CARBOXYVINYL- OR 1-NITRO-2-(DIMETHYLAMINO)VINYL-SUBSTITUTED IMIDAZOLIDINES OR TETRAHYDROPYRIMIDINES | NIHON BAYER AGROCHEM K.K. (JP) | 2000-02-08 | — | — | US | disclosed |
| US-5750704-A | INSECTICIDES | NIHON BAYER AGROCHEM K.K. (JP) | 1998-05-12 | — | — | US | disclosed |
| US-5580889-A | Insecticidal nitromethyl or niteoimino-heteromethyl-heterocyclics | NIHON BAYER AGROCHEM K.K. (JP) | 1996-12-03 | — | — | US | disclosed |
| US-5461167-A | 2-chloro-5-chloromethyl thiazole; insecticide | NIHON BAYER AGROCHEM K.K. (JP) | 1995-10-24 | — | — | US | disclosed |
| US-5298507-A | Insecticides | NIHON BAYER AGROCHEM K.K. (JP) | 1994-03-29 | — | — | US | disclosed |
| US-5204360-A | Insecticides | NIHON BAYER AGROCHEM K.K. (JP) | 1993-04-20 | — | — | US | disclosed |
| US-5001138-A | Insecticides | NIHON TOKUSHU NOYAKU SEIZO, K.K. (JP) | 1991-03-19 | — | — | US | disclosed |
| US-4845106-A | INSECTICIDES | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1989-07-04 | — | — | US | disclosed |
| US-4742060-A | 2-(NITROIMINO)- OR 2-(NITROMETHYLENE)-IMIDAZOLIDINES AS INSECTICIDES | NIHON TOKUSHU NOYAKU SEIZO K. K. (JP) | 1988-05-03 | — | — | US | disclosed |
| EP-0192060-A1 | Heterocyclic compounds | NIHON BAYER AGROCHEM K.K. (JP) | 1986-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327390-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | NR0B1, GRK1, GRIN1 | CYP3A4 1597/4885CYP2C19 1582/4885CYP1A2 1414/4885 |
| US-20240366615-A1 | POLQ INHIBITORS | POLQ, POLG, POLB | CYP3A4 2422/4885CYP2C19 1292/4885CYP1A2 1577/4885 |
| US-12414954-B2 | POLQ inhibitors | POLQ, POLG, POLB | CYP3A4 2422/4885CYP2C19 1292/4885CYP1A2 1577/4885 |
| US-20250195530-A1 | POLQ INHIBITORS | POLQ, POLG, POLB | CYP3A4 2422/4885CYP2C19 1292/4885CYP1A2 1577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.